AR127728A1 - NEW FUSION PROTEIN SPECIFIC FOR OX40 AND PD-L1 - Google Patents
NEW FUSION PROTEIN SPECIFIC FOR OX40 AND PD-L1Info
- Publication number
- AR127728A1 AR127728A1 ARP220103195A ARP220103195A AR127728A1 AR 127728 A1 AR127728 A1 AR 127728A1 AR P220103195 A ARP220103195 A AR P220103195A AR P220103195 A ARP220103195 A AR P220103195A AR 127728 A1 AR127728 A1 AR 127728A1
- Authority
- AR
- Argentina
- Prior art keywords
- fusion proteins
- proteins
- fusion protein
- protein specific
- new fusion
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 6
- 102000008096 B7-H1 Antigen Human genes 0.000 title abstract 3
- 108010074708 B7-H1 Antigen Proteins 0.000 title abstract 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 title abstract 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La descripción proporciona proteínas de fusión específicas tanto para OX40 como para PD-L1, en donde dichas proteínas pueden ser utilizadas para coestimular la activación de linfocitos de una manera dependiente de la diana PD-L1. Dichas proteínas de fusión pueden ser utilizadas en muchas aplicaciones farmacéuticas, por ejemplo como agentes anticáncer y/o moduladores inmunitarios. La presente descripción también se relaciona con métodos de preparación de las proteínas de fusión descriptas en la presente, así como con composiciones que comprenden dichas proteínas de fusión. La presente descripción se relaciona adicionalmente con moléculas de ácido nucleico que codifican dichas proteínas de fusión. Además, la solicitud describe usos terapéuticos y/o diagnóstico de dichas proteínas.The description provides fusion proteins specific for both OX40 and PD-L1, where said proteins can be used to costimulate lymphocyte activation in a manner dependent on the PD-L1 target. Such fusion proteins can be used in many pharmaceutical applications, for example as anticancer agents and/or immune modulators. The present description also relates to methods of preparing the fusion proteins described herein, as well as to compositions comprising said fusion proteins. The present disclosure further relates to nucleic acid molecules encoding said fusion proteins. Furthermore, the application describes therapeutic and/or diagnostic uses of said proteins.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21306614 | 2021-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127728A1 true AR127728A1 (en) | 2024-02-21 |
Family
ID=78821243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220103195A AR127728A1 (en) | 2021-11-19 | 2022-11-18 | NEW FUSION PROTEIN SPECIFIC FOR OX40 AND PD-L1 |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR127728A1 (en) |
TW (1) | TW202334203A (en) |
WO (1) | WO2023089079A1 (en) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
BR112018013911A2 (en) * | 2016-01-11 | 2018-12-18 | Inhibrx, Inc. | multivalent and multispecific ox40 binding fusion proteins |
BR112020013133A2 (en) * | 2017-12-29 | 2020-12-08 | Ap Biosciences, Inc. | MONOSPECIFIC AND BISPECIFIC PROTEINS WITH REGULATION OF THE IMMUNE CHECK POINT FOR CANCER THERAPY |
JP2022553176A (en) * | 2019-10-17 | 2022-12-22 | 江蘇康寧杰瑞生物制薬有限公司 | OX40/PD-L1 bispecific antibody |
-
2022
- 2022-11-18 WO PCT/EP2022/082368 patent/WO2023089079A1/en active Application Filing
- 2022-11-18 TW TW111144239A patent/TW202334203A/en unknown
- 2022-11-18 AR ARP220103195A patent/AR127728A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023089079A1 (en) | 2023-05-25 |
TW202334203A (en) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000207A1 (en) | New fusion proteins specific for cd137 and pd-l1 | |
Freyermuth-Trujillo et al. | Inflammation: a target for treatment in spinal cord injury | |
MX2021010039A (en) | Novel fusion proteins specific for cd137 and gpc3. | |
BR112022014623A2 (en) | ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND USES THEREOF | |
CL2017002767A1 (en) | New specific proteins for cd137. | |
EP4378962A3 (en) | Anti-cancer fusion polypeptide | |
BR112018068189A2 (en) | inducible binding proteins and methods of use | |
AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
BR112021005769A2 (en) | dll3 binding proteins and methods of use | |
BR112018072485A2 (en) | bispecific binding proteins and uses thereof | |
BR112017020445A2 (en) | fusion polypeptide, nucleic acid molecule, host cell, method of producing a fusion polypeptide, use of fusion polypeptide, method for activating signaling pathways, method for co-stimulating cells, method for inducing lymphocyte proliferation, and method for direct cd137 collation | |
BR112018016281A2 (en) | protease activatable bispecific t-cell activating molecule, idiotype-specific polypeptide, pharmaceutical composition, uses of the bispecific molecule and method of treating a disease in an individual | |
ECSP17061751A (en) | NEW SPECIFIC PROTEINS FOR PIOVERDIN AND PIOQUELIN | |
BR112022004047A2 (en) | Multispecific binding proteins for cancer treatment | |
BR112013019975A2 (en) | "Antigen binding proteins, pharmaceutical composition, use of an antigen binding protein, method for treating a patient and method for preparing an antigen binding protein, nucleic acid, vector and host cell" | |
UY33319A (en) | PROTEINS THAT JOIN TNF-a | |
MX2019014397A (en) | Polypeptides binding adamts5, mmp13 and aggrecan. | |
AR112069A1 (en) | IMMUNOGLOBULINS THAT BIND AGGRECAN | |
CO2020000369A2 (en) | Polypeptides that bind to the complement component c5 or serum albumin and their fusion proteins | |
MX2021000421A (en) | METHODS AND COMPOSITIONS USING RECOMBINANT DENDRITIC CELLS FOR THE TREATMENT OF CANCER. | |
BR112022021469A2 (en) | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEM | |
BR112022008201A2 (en) | SURFACE PROTEIN DEGRADATION USING B-SPECIFIC BINDING AGENT | |
MX2022001682A (en) | Novel antigen binding molecule formats. | |
BR112018075222A2 (en) | anti-tnfrsf25 antibodies | |
AR127728A1 (en) | NEW FUSION PROTEIN SPECIFIC FOR OX40 AND PD-L1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |